Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06040372 · ClinicalTrials.gov registry record · Phase 1
A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects
A Phase 1 study, sponsored by LG Chem.
- Completed
- Registry status
- Phase 1
- Development phase
- 112
- Enrollment target
NCT06040372: Completed Phase 1 study, sponsored by LG Chem.
NCT06040372 is a Phase 1 study that has completed, run by LG Chem. The registered enrollment target is 112 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06040372, a Phase 1 study, has completed, sponsored by LG Chem.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 112 participants
- Enrollment target
Study Summary
The aim of this 4-weeks randomized double-blind placebo-controlled single and multiple ascending dose study is to assess the Safety and Tolerability of LB54640 in Healthy overweight and obese subjects
Primary Outcome
Number of subjects who experienced adverse events and severity of adverse events
Interventions
- DRUG Placebo
- DRUG LB64640
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2020-03-16 |
| Est. Completion | 2022-07-30 |
| Phase | Phase 1 |
What the finished NCT06040372 record still lists
NCT06040372 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (87% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06040372 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06040372 about?
NCT06040372 is a clinical study titled "A First in Human Study to Assess the Safety, Tolerability of LB54640 in in Healthy Overweight and Obese Subjects". The aim of this 4-weeks randomized double-blind placebo-controlled single and multiple ascending dose study is to assess the Safety and Tolerability of LB54640 in Healthy overweight and obese subjects
What is the current status of trial NCT06040372?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 112 participants. The study started on 2020-03-16. Estimated completion is 2022-07-30.
What interventions are being tested in trial NCT06040372?
The interventions under investigation include: Placebo (DRUG), LB64640 (DRUG).
Who is sponsoring clinical trial NCT06040372?
This trial is sponsored by LG Chem, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06040372's enrollment target sits among peer trials
112 508th of 2000 higher than 1,489 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05024773 · 112 participants · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI